Femoropopliteal Stent Implantation

Eric A Secemsky^{1

2

3}, Ehrin J Armstrong^{4

5

6}

Affiliations

¹ Department of Medicine, Smith Center for Outcomes Research in Cardiology (E.A.S.).
² Division of Cardiology, Department of Medicine (E.A.S.), Beth Israel Deaconess Medical Center, Boston, MA.
³ Harvard Medical School, Boston, MA (E.A.S.).
⁴ University of Colorado School of Medicine, Aurora (E.J.A.).
⁵ Veterans Affairs Eastern Colorado Health Care System, Denver (E.J.A.).
⁶ Denver VA Medical Center, CO (E.J.A.).

Editorial

Eric A Secemsky et al. Circ Cardiovasc Interv. 2018 Aug.

. 2018 Aug;11(8):e007134.

doi: 10.1161/CIRCINTERVENTIONS.118.007134.

Eric A Secemsky^{1

2

3}, Ehrin J Armstrong^{4

5

6}

¹ Department of Medicine, Smith Center for Outcomes Research in Cardiology (E.A.S.).
² Division of Cardiology, Department of Medicine (E.A.S.), Beth Israel Deaconess Medical Center, Boston, MA.
³ Harvard Medical School, Boston, MA (E.A.S.).
⁴ University of Colorado School of Medicine, Aurora (E.J.A.).
⁵ Veterans Affairs Eastern Colorado Health Care System, Denver (E.J.A.).
⁶ Denver VA Medical Center, CO (E.J.A.).

No abstract available

Keywords: Editorials; alloys; humans; nitinol; peripheral artery disease.

Comment on

Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
Miura T, Miyashita Y, Soga Y, Hozawa K, Doijiri T, Ikeda U, Kuwahara K; DEBATE in SFA Investigators. Miura T, et al. Circ Cardiovasc Interv. 2018 Aug;11(8):e006564. doi: 10.1161/CIRCINTERVENTIONS.118.006564. Circ Cardiovasc Interv. 2018. PMID: 30354784 Clinical Trial.